Article
Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
American journal of hematology - 1 Nov 2021
Alwash Yasmin, Khoury Joseph D, Tashakori Mehrnoosh, Kanagal-Shamanna Rashmi, Daver Naval, Ravandi Farhad, Kadia Tapan M, Konopleva Marina, Dinardo Courtney D, Issa Ghayas C, Loghavi Sanam, Takahashi Koichi, Jabbour Elias, Guerra Veronica, Kornblau Steven, Kantarjian Hagop, Short Nicholas J
Abstract excerpt
TP53 mutations in acute myeloid leukemia (AML) are associated with resistance to standard treatments and dismal outcomes. The incidence and prognostic impact of the emergence of newly detectable TP53 mutations over the course of AML therapy has not been well described. We retrospectively analyzed 200 patients with newly diagnosed TP53 wild type AML who relapsed after or were refractory to frontline therapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.